閉塞性睡眠時無呼吸症および肥満または過体重の患者を対象としたエロラリンタイド（LY3841136）の研究

基本情報

NCT ID

NCT07369011

ステータス

募集前

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

800

治験依頼者名

Eli Lilly and Company

概要

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.

対象疾患

介入

依頼者（Sponsor）

実施施設 (11)